Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients

Swedish Orphan Biovitrum AB (OTC:BIOVF) and Sanofi SA (NASDAQ:SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated severe hemophilia A patients aged 12 and above.

  • The study met the primary endpoint, showing clinically meaningful prevention of bleeds in patients receiving weekly prophylaxis with efanesoctocog alfa over a period of 52 weeks. 
  • The median annualized bleeding rate (ABR) was 0 with a mean ABR of 0.71. 
  • The key secondary endpoint was also met, showing once-weekly efanesoctocog alfa was superior to prior prophylactic factor VIII replacement therapy.
  • The data showed a statistically significant reduction in ABR based on the intra-patient comparison. 
  • Efanesoctocog alfa was well-tolerated, and inhibitor development to factor VIII was not detected. The most common treatment-emergent adverse events were headache, arthralgia, fall, and back pain.
  • The data will be the basis for submission to regulatory authorities expected to start in 2022.
  • Submission in the EU will follow the availability of data from the ongoing XTEND-Kids pediatric study, expected in 2023. 
  • Price Action: SNY shares are up 2.27% at $51.34 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.